AXSM250117P75000
- 0.50
- +0.20+66.67%
Axsome Therapeutics Newsroom
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $180
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $140
RBC Lifts Price Target on Axsome Therapeutics to $140 From $138, Keeps Outperform Rating
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $133
Axsome Therapeutics Price Target Maintained With a $133.00/Share by Needham
Axsome Therapeutics Analyst Ratings
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Axsome Therapeutics Is Maintained at Outperform by Mizuho
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Leerink Partners Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $110
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $124
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $180
Buy Rating for Axsome Therapeutics: Promising AXS-05 Efficacy in Alzheimer's Agitation
Mizuho Trims Price Target on Axsome Therapeutics to $122 From $124, Keeps Outperform Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM) and Ascendis Pharma (ASND)
Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Axsome Therapeutics Analyst Ratings